Evidence map›Paper›PMID 27708557›Full record

ArticleClinical proteomics2016

Plasma degradome affected by variable storage of human blood.

Maria Kaisar, Leon F A van Dullemen, Marie-Laëtitia Thézénas, M Zeeshan Akhtar, Honglei Huang, Sandrine Rendel, Philip D Charles, Roman Fischer, Rutger J Ploeg, Benedikt M Kessler

Open access · goldAbstract read
In one paragraph

Article in Clinical proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Cytoskeletal protein degradation in brain death donor kidneys associates with adverse posttransplant outcomes.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands) · 2019 · on this map
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Maria KaisarNuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 7LJ UK.
Leon F A van Dullemen *Surgical Research Laboratory, University Medical Center, University of Groningen, Groningen, 9713 GZ The Netherlands.
Marie-Laëtitia Thézénas *Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ UK.
M Zeeshan AkhtarNuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 7LJ UK.
Honglei HuangNuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 7LJ UK.
Sandrine RendelNuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 7LJ UK.
Philip D CharlesTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ UK.
Roman FischerTarget Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ UK.
Rutger J Ploeg *Nuffield Department of Surgical Sciences, University of Oxford, Oxford, OX3 7LJ UK.
Benedikt M Kessler *Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7FZ UK.ORCID 0000-0002-8160-2446
University of Oxford · GBNuffield Orthopaedic Centre · GBNHS Blood and Transplant · GBUniversity Medical Center Groningen · NL

Funding

Wellcome Trust
6 · The paper itself

Abstract

backgroundThe successful application of-omics technologies in the discovery of novel biomarkers and targets of therapeutic interventions is facilitated by large collections of well curated clinical samples stored in bio banks. Mining the plasma proteome holds promise to improve our understanding of disease mechanisms and may represent a source of biomarkers. However, a major confounding factor for defining disease-specific proteomic signatures in plasma is the variation in handling and processing of clinical samples leading to protein degradation. To address this, we defined a plasma proteolytic signature (degradome) reflecting pre-analytical variability in blood samples that remained at ambient temperature for different time periods after collection and prior to processing.

methodsWe obtained EDTA blood samples from five healthy volunteers (n = 5), and blood tubes remained at ambient temperature for 30 min, 8, 24 and 48 h prior to centrifugation and isolation of plasma. Naturally occurred peptides derived from plasma samples were compared by label-free quantitative LC-MS/MS. To profile protein degradation, we analysed pooled plasma samples at T = 30 min and 48 h using PROTOMAP analysis. The proteolytic pattern of selected protein candidates was further validated by immunoblotting.

resultsA total of 820 plasma proteins were surveyed by PROTOMAP, and for 4 % of these, marked degradation was observed. We show distinct proteolysis patterns for talin-1, coagulation factor XI, complement protein C1r, C3, C4 and thrombospondin, and several proteins including S100A8, A9, annexin A1, profiling-1 and platelet glycoprotein V are enriched after 48 h blood storage at ambient temperature. In particular, thrombospondin protein levels increased after 8 h and proteolytic fragments appeared after 24 h storage time.

conclusionsThe overall impact of blood storage at ambient temperature for variable times on the plasma proteome and degradome is relatively minor, but in some cases can cause a potential bias in identifying and assigning relevant proteomic markers. The observed effects on the plasma proteome and degradome are predominantly triggered by limited leucocyte and platelet cell activation due to blood handling and storage. The baseline plasma degradome signature presented here can help filtering candidate protein markers relevant for clinical biomarker studies.

Indexed as

Ambient temperatureBiobankMass spectrometryPlasma proteomePre analytical variabilityPROTOMAPQUOD

Identifiers

PMID27708557
PMCPMC5037888
OpenAlexW2527374233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.